The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Identification of a novel mitochondrial protein (“mitoNEET”) cross-linked specifically by a thiazolidinedione photoprobe
Abstract
Thiazolidinediones address underlying causes of type 2 diabetes, although their mechanism of action is not clearly understood. The compounds are thought to function as direct activators of the nuclear receptor PPARγ (peroxisome proliferator-activated receptor-γ), although pioglitazone, the weaker agonist of the two thiazolidinediones now in clinical use, seems to have more useful effects on circulating lipids. We have used tritiated pioglitazone and a photoaffinity cross-linker to identify a novel binding site in mitochondria. A saturable binding site for [3 H]pioglitazone was solubilized from the membranes with CHAPS and migrated as a large complex by size exclusion chromatography. The binding correlated with a <17-kDa protein (m17), marked by a photoaffinity cross-linker, in both subcellular location and selectivity of competition by analogs. The protein was isolated and identified by mass spectrometry analysis and NH 2-terminal sequencing. Three synthetic peptides with potential antigenic properties were synthesized from the predicted nontransmembrane sequence to generate antibodies in rabbits. Western blots show that this protein, which we have termed “mitoNEET,” is located in the mitochondrial fraction of rodent brain, liver, and skeletal muscle, showing the identical subcellular location and migration on SDS-PAGE as the protein cross-linked specifically by the thiazolidinedione photoprobe. The protein exists in low levels in preadipocytes, and expression increases exponentially in differentiated adipocytes. The synthetic protein bound to solid phase associated with a complex of solubilized mitochondrial proteins, including the trifunctional β-oxidation protein. It is possible that thiazolidinedione modification of the function of the mitochondrial target may contribute to lipid lowering and/or antidiabetic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Yu, C., Chen, Y., Cline, G. W., Zhang, D., Zong, H., Wang, Y., Bergeron, R., Kim, J. K., Cushman, S. W., Cooney, G. J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200958200 · Cited by 1,561
Peroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3216-3 · Cited by 1,218
Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 1×
“Thus not all PPAR activators have antidiabetic actions (30), and some potent antidiabetic analogs are not good PPAR activators (5, 37, 42).”
BackgroundThiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Malonyl-CoA, fuel sensing, and insulin resistance
Ruderman, N. B., Saha, A. K., Vavvas, D., & Witters, L. A. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.276.1.e1 · Cited by 650
Willson, T. M., Cobb, J. E., Cowan, D. J., Wiethe, R. W., Correa, I. D., Prakash, S. R., Beck, K. D., Moore, L. B., Kliewer, S. A., & Lehmann, J. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950395a · Cited by 638
Chavez, J. A., Knotts, T. A., Wang, L.-P., Li, G., Dobrowsky, R. T., Florant, G. L., & Summers, S. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212307200 · Cited by 617 · cited 1×
“The buildup of long-chain acyl-CoA esters could result in insulin resistance by a number of mechanisms, including activation of specific protein kinase C isoforms (50) or generation of ceramide (7).”
BackgroundA futile metabolic cycle activated in adipocytes by antidiabetic agents
Guan, H.-P., Li, Y., Jensen, M. V., Newgard, C. B., Steppan, C. M., & Lazar, M. A. (2002) · Nature Medicine · doi:10.1038/nm780 · Cited by 428
Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency
Miles, P. D. G., Barak, Y., He, W., Evans, R. M., & Olefsky, J. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8538 · Cited by 400
An Essential Regulator of Adipogenesis and Modulator of Fat Cell Function: PPARγ
Lowell, B. B. (1999) · Cell · doi:10.1016/s0092-8674(00)81654-2 · Cited by 383
Troglitazone action is independent of adipose tissue.
Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S., & Graves, R. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119839 · Cited by 334
The Peroxisome Proliferator-Activated Receptor-γ2 Pro12Ala Polymorphism
Stumvoll, M., & Häring, H. (2002) · Diabetes · doi:10.2337/diabetes.51.8.2341 · Cited by 332
Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., & Suzuoki, Z. (1983) · Diabetes · doi:10.2337/diab.32.9.804 · Cited by 286
Enhancement of adipocyte differentiation by an insulin-sensitizing agent.
Kletzien, R. F., Clarke, S. D., & Ulrich, R. G. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08890-x · Cited by 284
PPARγ and the Treatment of Insulin Resistance
OLEFSKY, J., & SALTIEL, A. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00306-4 · Cited by 279
The Pro12Ala Polymorphism in PPAR γ2 May Confer Resistance to Type 2 Diabetes
Hara, K., Okada, T., Tobe, K., Yasuda, K., Mori, Y., Kadowaki, H., Hagura, R., Akanuma, Y., Kimura, S., Ito, C., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2605 · Cited by 273
Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ
Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., & Berkenstam, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31108 · Cited by 260
Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5
Kim, J.-H., Lewin, T. M., & Coleman, R. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010793200 · Cited by 252
Khan, M. A., St. Peter, J. V., & Xue, J. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.708 · Cited by 250
Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.
Ikeda, H., Taketomi, S., Sugiyama, Y., Shimura, Y., Sohda, T., Meguro, K., & Fujita, T. (1990) · PubMed · Cited by 191
Prohibitin, an antiproliferative protein, is localized to mitochondria
Ikonen, E., Fiedler, K., Parton, R. G., & Simons, K. (1995) · FEBS Letters · doi:10.1016/0014-5793(94)01444-6 · Cited by 187
Reginato, M. J., Bailey, S. T., Krakow, S. L., Minami, C., Ishii, S., Tanaka, H., & Lazar, M. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32679 · Cited by 185
Rosiglitazone: A Review of its Use in the Management of Type 2 Diabetes Mellitus
Wagstaff, A. J., & Goa, K. L. (2002) · Drugs · doi:10.2165/00003495-200262120-00007 · Cited by 175
Boyle, P. J., King, A. B., Olansky, L., Marchetti, A., Lau, H., Magar, R., & Martin, J. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85040-8 · Cited by 161
Muscle Long‐Chain Acyl CoA Esters and Insulin Resistance
Cooney, G. J., Thompson, A. L., Furler, S. M., Ye, J.-M., & Kraegen, E. W. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04276.x · Cited by 150
Cross-linking in the living cell locates the site of action of oxazolidinone antibiotics
Colca, J. R., McDonald, W. G., Waldon, D. J., Thomasco, L. M., Gadwood, R. C., Lund, E. T., Cavey, G. S., Mathews, W. R., Adams, L. D., Cecil, E. T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302109200 · Cited by 139
Self-citationChang, A. Y., Wyse, B. M., Gilchrist, B. J., Peterson, T., & Diani, A. R. (1983) · Diabetes · doi:10.2337/diab.32.9.830 · Cited by 138
Role of Skeletal Muscle in Thiazolidinedione Insulin Sensitizer (PPAR Agonist) Action
Zierath, J. R., Ryder, J. W., Doebber, T. W., Woods, J. W., Wu, M. S., Ventre, J. R., Li, Z., McCrary, C. T., Berger, J. P., Zhang, B., et al. (1998) · Endocrinology · doi:10.1210/endo.139.12.6364 · Cited by 136
Kletzien, R. F., Foellmi, L. A., Harris, P. K., Wyse, B. M., & Clarke, S. D. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08970-9 · Cited by 108
Brunmair, B., Gras, F., Neschen, S., Roden, M., Wagner, L., Waldhäusl, W. K., & Fürnsinn, C. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2309 · Cited by 105
Thiazolidinediones: metabolic actions in vitro
Fürnsinn, C., & Waldhäusl, W. K. (2002) · Diabetologia · doi:10.1007/s00125-002-0899-1 · Cited by 101
Thiazolidinediones--tools for the research of metabolic syndrome X.
Komers, R., & Vrána, A. (1998) · PubMed · Cited by 98
Gegick, C. G., & Altheimer, M. D. (2001) · Endocrine Practice · doi:10.4158/ep.7.3.162 · Cited by 89
Hasstedt, S. J., Ren, Q.-F., Teng, K., & Elbein, S. C. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7205 · Cited by 89
Localization of a pioglitazone response element in the adipocyte fatty acid-binding protein gene.
Harris, P. K. W., & Kletzien, R. F. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10015-1 · Cited by 84
The mitochondrial trifunctional protein: centre of a β-oxidation metabolon?
Eaton, S., Bursby, T., Middleton, B., Pourfarzam, M., Mills, K., Johnson, A. W., & Bartlecc, K. (2000) · Biochemical Society Transactions · doi:10.1042/bst0280177 · Cited by 82
Saha, A. K., Kurowski, T. G., Colca, J. R., & Ruderman, N. B. (1994) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1994.267.1.e95 · Cited by 78
Self-citationTanis, S. P., Parker, T. T., Colca, J. R., Fisher, R. M., & Kletzein, R. F. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9605694 · Cited by 71
Self-citationPreadipocyte differentiation in vitro: Identification of a highly active adipogenic agent
Hiragun, A., Sato, M., & Mitsui, H. (1988) · Journal of Cellular Physiology · doi:10.1002/jcp.1041340115 · Cited by 60
Differences in Lipid Profiles of Patients Given Rosiglitazone Followed by Pioglitazone
LaCivita, K. A., & Villarreal, G. E. (2002) · Current Medical Research and Opinion · doi:10.1185/030079902125001038 · Cited by 43
Hasstedt, S. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.536 · Cited by 41
Ye, J., Frangioudakis, G., Iglesias, M. A., Furler, S. M., Ellis, B. A., Dzamko, N. L., Cooney, G. J., & Kraegen, E. W. (2002) · Endocrinology · doi:10.1210/en.2002-220387 · Cited by 37
Review: Thiazolidinediones today
Bailey, C. J., & Day, C. (2001) · The British Journal of Diabetes · doi:10.1177/14746514010010010201 · Cited by 30
Thiazolidinediones: A Pharmacological Overview
Owens, D. R. (2002) · Clinical Drug Investigation · doi:10.2165/00044011-200222080-00001 · Cited by 28
Sizer, K. M., Smith, C. L., Jacob, C. S., Swanson, M. L., & Bleasdale, J. E. (1994) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(94)90105-8 · Cited by 23
Synthetic ligands for PPARγ - review of patent literature 1994 - 1999
Rami, H. K., & Smith, S. A. C. (2000) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.10.5.623 · Cited by 16
Cited by
A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging
Tanenbaum, M. E., Gilbert, L. A., Qi, L. S., Weissman, J. S., & Vale, R. D. (2014) · Cell · doi:10.1016/j.cell.2014.09.039 · Cited by 1,580
Iron Metabolism in Ferroptosis
Chen, X., Yu, C., Kang, R., & Tang, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.590226 · Cited by 959
Mitochondrial dysfunction in Nash: causes, consequences and possible means to prevent it
Begriche, K., Igoudjil, A., Pessayre, D., & Fromenty, B. (2006) · Mitochondrion · doi:10.1016/j.mito.2005.10.004 · Cited by 753
Simcox, J. A., & McClain, D. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.02.007 · Cited by 545
CISD1 inhibits ferroptosis by protection against mitochondrial lipid peroxidation
Yuan, H., Li, X., Zhang, X., Kang, R., & Tang, D. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.08.034 · Cited by 504
Metadata
- Authors
- Colca, J. R., McDonald, W. G., Waldon, D. J., Leone, J. W., Lull, J. M., Bannow, C. A., Lund, E. T., & Mathews, W. R.
- Venue
- American Journal of Physiology-Endocrinology and Metabolism
- Publisher
- American Physiological Society
- Published
- 2004-02
- Volume
- 286
- Issue
- 2
- Pages
- E252-E260
- ISSN
- 0193-1849 (ISSN-L)
- 1522-1555
- OpenAlex
- W2116048591
- Cited by
- 338
- References
- 48
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.